We further performed a detailed survey of QTLs for all obesity-related phenotypes such as body weight, fat mass, lean mass and leptin levels.
*Cirrhotic vs. controls (p = 0.001), ** cirrhotic females vs. control females (p = 0.025), ***Cirrhotic males vs. control males (p = 0.002) BMI; Body mass index, BFP; Body fat percentage, BFM; Body fat mass Serum leptin levels were significantly higher in cirrhotic group than controls (p = 0.001) (Table 1).
It also decreases fat mass and leptin levels.
This was accompanied by a decrease in total fat mass, circulating leptin levels, plasma triglyceride concentration, and a signaling metabolite in liver, malonyl-CoA, that inhibits fatty acid degradation.
As to NCCM risk factors, women had higher median fat mass and leptin levels than men.
Body weight, fat mass, and leptin levels were significantly lower in AgRPp110β null mice.
POMCp110α null mice, in contrast, displayed normal body weight, fat mass, and leptin levels.
AFABP in cord blood serum was found to correlate with both neonatal fat mass and leptin levels in GDM but not in control subjects.
On HFD, AgRPp110β null, but not AgRPp110α null, mice displayed a significant reduction in body weight, fat mass, and leptin levels, compared to controls.
Consistent with reduced fat and lean mass, low leptin levels, and the hypothesized increase in sympathetic tone in VGF mutant mice, significant reductions in both bone density and bone mineralization were also noted in VGFR knockout mice.
